Role of the @entity916 -angiotensin system in @entity1283 and @entity8 in transgenic XXXX @entity19 carrying both @entity1 @entity916 and @entity2178 genes.

@entity1 @entity8 @entity101 @entity19 @entity2178 @entity1283 @entity2514 @entity3593 @entity916
Tsukuba @entity101 @entity19 (THMs) are @entity19 carrying @entity1 @entity916 and @entity2178 genes. The aim of this study was to evaluate the role of the @entity916 -angiotensin system (RAS) in @entity1283 and @entity8 in THMs. After a 2-wk control period, 10-wk-old THMs were treated with @entity3593 (ACEI group) or @entity2514 ( @entity2514 group) or left untreated (control group) for 8 wk. C57BL/6 @entity19 of similar age (wild group) were used as normal controls. Systolic blood pressure and urinary albumin excretion were measured once a week. All @entity19 were sacrificed at 20 wk of age, and heart to body weight ratio, cardiac myocyte diameter, @entity8 index, and glomerular size were measured. Fibronectin expression was also evaluated. At 20 wk of age, systolic blood pressure and urinary albumin excretion in the control group were significantly higher than those in the wild group and significantly lower than those in the ACEI and @entity2514 groups. Heart to body weight ratio and cardiac myocyte diameter were significantly higher in the @entity2514 and control groups than in the other groups. @entity8 index and glomerular size were also significantly higher in the control group than in the other groups, and there were significant differences between the ACEI and @entity2514 groups in these variables. Fibronectin expression was marked in the control and @entity2514 groups. These findings suggest that the RAS plays an important role in @entity1283 in THMs, but that both the RAS and elevation of blood pressure contribute to the pathogenesis of @entity8 .
